You just read:

Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

News provided by

Bayer HealthCare Pharmaceuticals Inc.

18 Feb, 2014, 02:15 ET